
Viking Therapeutics Surges on Landmark Obesity Drug Trial Data as Market Leaders Eli Lilly and Novo Nordisk Face Downward Pressure
Viking Therapeutics shares skyrocketed in premarket trading following positive trial data for its dual-action obesity treatment, while established market giants Eli Lilly and Novo Nordisk experienced slight pullbacks. Simultaneously, broader sector movements highlighted technical strength across pharmaceutical portfolios.


























































































